Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients

European Journal of Endocrinology

Volumn 150, Issue 5, 2004, Pages 663-669

  Ronchi, C L ^b   Corbetta, S ^b   Cappiello, V ^b   Morpurgo, P S ^b   Giavoli, C ^b   Beck Peccoz, P ^b   Arosio, M ^a   Spada, Anna ^b  

^a S Giuseppe Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GHRELIN; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPID; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHRONIC DISEASE; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENDER; HOMEOSTASIS; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; MORTALITY; NONBIOLOGICAL MODEL; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ACROMEGALY; ADIPONECTIN; ADIPOSE TISSUE; ADULT; ANIMALS; ANTHROPOMETRY; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; GLUCOSE; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; PROTEINS; RISK FACTORS;

EID: 2942705702     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500663     Document Type: Article

References (36)

1. Diez JJ & Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. European Journal of Endocrinology 2003 148 293-300.
2. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. Journal of Biological Chemistry 2003 278 2461-2468.
3. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001 103 1057-1063.
4. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R & Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. Journal of Clinical Endocrinology and Metabolism 2003 88 2714-2718.
5. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 2001 86 1930-1935.
6. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL & Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. European Journal of Endocrinology 2003 149 331-335.
7. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001 7 941-946.
8. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. PNAS 2001 98 2005-2010.
9. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 1999 257 79-83.
10. Haque WA, Shimomura I, Matsuzawa Y & Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. Journal of Clinical Endocrinology and Metabolism 2002 87 2395-2398.
11. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis, Thrombosis and Vascular Biology 2000 20 1595-1599.
12. Kishida K, Nagaretani H, Kondo H, Kobayashi H, Tanaka S, Maeda N et al. Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. Biochemical and Biophysical Research Communications 2003 306 286-292.
13. Matsubara M, Maruoka S & Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. Journal of Clinical Endocrinology and Metabolism 2002 87 2764-2769.
14. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F & Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. American Journal of Hypertension 2003 16 72-75.
15. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arteriosclerosis, Thrombosis and Vascular Biology 2003 23 85-89.
16. Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Vujisic B, Petrovic M et al. High output heart failure in patients with newly diagnosed acromegaly. American Journal of Medicine 2002 112 610-616.
17. Melmed S. Acromegaly. New England Journal of Medicine 1990 322 966-977.
18. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M & Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. American Journal of Physiology 1986 250 E269-E273.
19. Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE et al. Basal and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. Journal of Clinical Endocrinology and Metabolism 1992 74 1012-1019.
20. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clinical Endocrinology 2000 52 549-555.
21. Ronchi CL, Orsi E, Giavoli C, Cappiello V, Epaminonda P, Beck-Peccoz P et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. Journal of Endocrinological Investigation 2003 26 533-538.
22. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G & Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000 151 551-557.
23. Clayton RN. Cardiovascular function in acromegaly. Endocrine Reviews 2003 24 272-277.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII). Journal of the American Medical Association 2001 287 356-359.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
26. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and Metabolism 2000 85 2402-2410.
27. Silha JV, Krsek M, Hana V, Marek J, Jezkova J, Weiss V et al. Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clinical Endocrinology 2003 58 736-742.
28. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Ravussin E, Weyer C et al. Plasma adiponectin levels are not associated with fat oxidation in humans. Obesity Research 2002 10 1016-1020.
29. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003 46 459-469.
30. Brummer RJM, Lonn L, Kvist H, Grangard U, Bengtsson BA & Sjostrom L. Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy. European Journal of Clinical Investigation 1993 23 199-205.
31. Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H & Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 3476-3479.
32. Cappiello V, Ronchi C, Morpurgo PS, Epaminonda P, Arosio M, Beck-Peccoz P et al. Circulating ghrelin levels in basal conditions and during glucose tolerance test in acromegalic patients. European Journal of Endocrinology 2002 147 189-194.
33. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschop M & Pasquali R. Plasma ghrelin, obesity and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. Journal of Clinical Endocrinology and Metabolism 2002 87 5625-5629.
34. Fasshauer M, Klein J, Neumann S, Eszlinger M & Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications 2002 290 1084-1089.
35. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochemical and Biophysical Research Communications 2001 288 1102-1107.
36. Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clinical Endocrinology 2001 54 515-524.